Revenue Growth - Revenues reached $1.4 million in the first nine months of 2024, a 51% increase compared to the same period in 2023[1] - Revenues for the three months ended September 30, 2024, increased to $482,000, up 34% from $360,000 in the same period of 2023[19] - E-commerce sales increased approximately 20% in Q3 2024 compared to Q3 2023, representing about 35% of year-to-date 2024 sales[2] Gross Margin and Profit - Gross margin improved to 65% in Q3 2024 from 49% in Q3 2023, with gross profit dollars increasing by 79%[1] - Gross profit for the nine months ended September 30, 2024, was $699,000, representing a 70% increase compared to $410,000 for the same period in 2023[19] Operating Expenses - Operating expenses decreased by 12% in Q3 2024 compared to Q3 2023, reflecting tight expense control[1] - Selling, general and administrative expenses decreased to $1,411,000 for the three months ended September 30, 2024, down 19% from $1,748,000 in the same period of 2023[19] - Total operating expenses for the nine months ended September 30, 2024, were $5,691,000, down 11% from $6,406,000 in the same period of 2023[19] Product Performance - Evolve Rat product contributed approximately 52% of Q3 2024 revenue, with sales increasing by 11% compared to Q2 2024[2] - Evolve Mouse, launched in May 2024, contributed 17% of Q3 2024 revenue[2] - New product packaging launched for Evolve uses 87% less plastic than traditional pails, enhancing gross margins[3] Financial Loss and Adjusted EBITDA - The net loss for the three months ended September 30, 2024, was $1,513,000, a reduction of 22% compared to a net loss of $1,947,000 in the same period of 2023[19] - Adjusted EBITDA loss for the three months ended September 30, 2024, was $1,418,000, an improvement from a loss of $1,787,000 in the same period of 2023[20] Future Outlook - The Company expects to achieve cash flow breakeven in the near term due to accelerating revenue growth and improved gross margins[4] - The Company is negotiating with New York City for a rat contraception pilot program, responding to city requests[3] Other Financial Metrics - Research and development expenses for the three months ended September 30, 2024, rose to $451,000, a 19% increase from $379,000 in the prior year[19] - Weighted average shares outstanding for the three months ended September 30, 2024, increased significantly to 729,400 from 34,805 in the same period of 2023[19] - Loss per share for the three months ended September 30, 2024, was $(2.07), compared to $(55.93) in the same period of 2023[19] - Other income for the three months ended September 30, 2024, increased to $34,000, compared to $4,000 in the same period of 2023[19]

Record Revenue and Margin PerformancePHOENIX, Nov. 12, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations and the only manufacturer of commercial and consumer available EPA-registered Rat Birth Control® products today announced financial results for the third quarter of 2024.Recent Highlights Revenues of $1.4 million in the first nine months of 2024, an increase of 51% compared to the same period of 2023. Gross ...

Core Insights - SenesTech, Inc. has announced a significant expansion of its rodent birth control products, Evolve™ Rat and Evolve™ Mouse, now available on Walmart Marketplace, enhancing market reach and accessibility for consumers [1][3][5] Product Overview - Evolve is a proprietary technology developed by SenesTech for managing rat and mouse populations through fertility control, offering a minimum-risk soft bait that is safe for people, pets, wildlife, and the environment [2][6] - The product targets the reproductive capabilities of both male and female rodents, leading to a significant reduction in populations within 2-3 months of continuous use [3][4] Market Context - The expansion into Walmart Marketplace is expected to significantly contribute to the growth and adoption of Evolve, aligning with increasing consumer demand for humane and sustainable pest management solutions as traditional poisons face regulatory restrictions [4][5] - The company emphasizes that two rats can produce up to 15,000 offspring in a year if left unchecked, highlighting the urgency of addressing rodent overpopulation [4] Company Mission - SenesTech is committed to creating healthier environments through humane pest management, aiming to reduce reliance on traditional poisons and enhance the effectiveness of pest management programs [6]

Financial results to be released after market close; Conference call to be conducted at 5:00 pm ETPHOENIX, Nov. 5, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its third quarter 2024, ended September 30, 2024, after the market close on Tuesday, November 12, 2024. The Company has scheduled a conference call that same day, Tuesday, November 12, 2024, at 5:00 pm ET, to review the results.Third Quarter 2024 Conference Call DetailsDate and Time: Tuesday, November 12, 2024 ...

PHOENIX, Oct. 31, 2024 /PRNewswire/ -- SenesTech, Inc. (Nasdaq: SNES), the leader in birth control to manage rodent pest populations, today announces the successful registration of Evolve™ in Hong Kong.A Sustainable and Humane Approach to Rodent ControlHong Kong welcomes Evolve™, an innovative, non-lethal rodent birth control solution designed to target rat infestations at their root. Unlike conventional methods, Evolve restricts rodent reproduction, offering an effective and humane way to manage infestatio ...

PHOENIX, Sept. 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today it will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024. Company Webcast The webcasted presentation will take place at 11:00am ET on Tuesday, October 1, 2024. The we ...

PHOENIX, Aug. 23, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, announced today the closing of an exercise of certain existing warrants to purchase 505,502 shares of the Company's common stock at a reduced exercise price of $4.60 per share. In addition, the Company issued new warrants, as described below. The aggregate gross proceeds from the exercise of ...

Record Revenue and Margin Performance PHOENIX, Aug. 8, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), the leader in fertility control to manage animal pest populations and the only manufacturer of commercially available, EPA-registered Rat Birth Control® products today announced financial results for the second quarter of 2024. | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------- ...

Financial results to be released after market close; Conference call to be conducted at 5:00 pm ET PHOENIX, Aug. 1, 2024 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES) will report financial results for its second quarter 2024, ended June 30, 2024, after the market close on Thursday, August 8, 2024. The Company has scheduled a conference call that same day, Thursday, August 8, 2024, at 5:00 pm ET, to review the results. Second Quarter 2024 Conference Call Details Date and Time: Thursday, August 8, 2024, at 5 ...

The GotStocks Podcast puts the small-cap sector in the limelight with in-depth interviews featuring executives responsible for guiding gems that could be on the cusp of huge moves. The latest episode features Joel Fruendt, President and CEO of SenesTech Inc. (NASDAQ:SNES), the leader in fertility control to manage animal pest populations. To begin the interview, Fruendt provided an introduction to SenesTech® and its business model. "I'll start out with this fact that usually leaves people with their jaws dr ...